**Table 1. Clinical trials of exosomal PD-L1 in cancer**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Patient Population** | **Phase** | **Status** | **Participants** | **Treatment** | **Outcome Measures** | **ClinicalTrials.gov Identifier** |
| OSAS, Obstructive Cancer | NA | Not yet recrulting | 90  | Diagnostic test: Liquid biopsy | Exosomal PD1 / PD-L1 expression | NCT02890849 |
| NSCLC | I | Unknown | 60  | Liquid biopsy | Explore the consistency analysis of PD-L1 expression level detected in cancer tissues and exosome | NCT02890849 |
| NSCLC | I | Unknown | 60  | Five kinds of radiation-division with bioequivalent doses | The match rate of PD-L1 expression in tumor tissue and PD-L1 mRNA expression in plasma exosomes before / after radiotherapy | NCT02869685 |
| Lymphoma | I/II | Recrulting | 48  | Pembrolizumab given intravenously at a fixed dose of 200 mg every 3 weeks for up to 36 cycles | PD1/PD-L1 expression on TILs and exosomes | NCT02535247 |
| CRC | II | Recrulting | 40  | Participants received SBRT (BED>80Gy) to oligometastatic lesions and then receive Toripalimab (240mg)/q3w till progression of disease | Change of PD-L1 on exosomes/CTCs | NCT03927898 |

Abbreviations: OSAS, obstructive sleep apnea syndromes; NSCLC, non-small cell lung cancer; NA, not applicable; TILs, tumor infiltrating lymphocytes; CRC, colorectal cancer; SRBT, stereotactic body radiation therapy; CTCs, circulating tumor cells